Author

Miriam Mañosa Ciria

Mistakes in the management of postoperative Crohn’s disease and how to avoid them
Mistakes in the management of postoperative Crohn’s disease and how to avoid them

Miriam Mañosa Ciria  et al.

UEG Webinar | Mistakes in the management of postoperative Crohn’s disease and how to avoid them
UEG Webinar | Mistakes in the management of postoperative Crohn’s disease and how to avoid them

Miriam Mañosa Ciria  et al.

LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT
LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT

Miriam Mañosa Ciria  et al.

Webinar en español | Aplicación práctica de nuevos tratamientos de la Colitis Ulcerosa
Webinar en español | Aplicación práctica de nuevos tratamientos de la Colitis Ulcerosa

Miriam Mañosa Ciria  et al.

THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL
THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL

Miriam Mañosa Ciria  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Miriam Mañosa Ciria  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Miriam Mañosa Ciria  et al.

COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

Miriam Mañosa Ciria  et al.

MANAGEMENT AND OUTCOMES OF LOWER GASTROINTESTINAL BLEEDING IN PATIENTS ON ANTICOAGULATION
MANAGEMENT AND OUTCOMES OF LOWER GASTROINTESTINAL BLEEDING IN PATIENTS ON ANTICOAGULATION

Miriam Mañosa Ciria  et al.

HIGHER PERFORMANCE OF FAECAL MICROBIAL MARKERS TO MONITOR ENDOSCOPIC ACTIVITY IN CROHN’S DISEASE, AS COMPARED TO FAECAL CALPROTECTIN
HIGHER PERFORMANCE OF FAECAL MICROBIAL MARKERS TO MONITOR ENDOSCOPIC ACTIVITY IN CROHN’S DISEASE, AS COMPARED TO FAECAL CALPROTECTIN

Miriam Mañosa Ciria  et al.

CHARACTERIZATION OF THE FATTY ACID PROFILE OF THE CREEPING FAT OF CROHN’S DISEASE IN COMPARISON TO INFLAMMATORY BOWEL DISEASE-FREE CONTROLS
CHARACTERIZATION OF THE FATTY ACID PROFILE OF THE CREEPING FAT OF CROHN’S DISEASE IN COMPARISON TO INFLAMMATORY BOWEL DISEASE-FREE CONTROLS

Miriam Mañosa Ciria  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Miriam Mañosa Ciria  et al.

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

Miriam Mañosa Ciria  et al.

PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)
PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)

Miriam Mañosa Ciria  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Miriam Mañosa Ciria  et al.

HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Miriam Mañosa Ciria  et al.

Item 1 - 16 / 16
1